Non-core divestments in pharma could herald an increase in IP-rich deal making

Non-core divestments in pharma could herald an increase in IP-rich deal making

Merck Group, Pfizer and Eli Lilly have, in quick succession, announced that they are considering moves to sell large, non-core parts of their businesses. Intellectual property, and its valuation, would inevitably play a large part in such…

Unlock unlimited access to all IAM content